CC
TAK icon

CQS Cayman’s Takeda Pharmaceutical TAK Stock Holding History

CQS Cayman’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$955K Hold
55,500
– – 0.04% 143
2019
Q2 		$982K Hold
55,500
– – 0.04% 142
2019
Q1 		$1.13M Hold
55,500
– – 0.05% 91
2018
Q4 		$934K Buy
+55,500
New +$937K 0.06% 93

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

CQS Cayman's TAK Position: Q3 2019 in Review

CQS Cayman held its Takeda Pharmaceutical (TAK) position steady in Q3 2019 at 55,500 shares worth $955K. The position accounts for 0.04% of the portfolio, ranked #143.

CQS Cayman first reported a position in TAK in Q4 2018 and has held it in 4 quarters since. The position peaked at $1.13M in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • CQS Cayman held 55,500 shares of Takeda Pharmaceutical worth $955K as of Q3 2019.
  • CQS Cayman left its Takeda Pharmaceutical share count unchanged in Q3 2019.
  • Takeda Pharmaceutical made up 0.04% of CQS Cayman's portfolio in Q3 2019, its #143 holding.
  • CQS Cayman first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 4 quarters since.
  • CQS Cayman's Takeda Pharmaceutical position peaked at $1.13M in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on CQS Cayman's 13F filing for Q3 2019, filed 12 Nov 2019.